MediciNova begins producing vector for its intranasal COVID-19 vaccine

By The Science Advisory Board staff writers

November 24, 2020 -- MediciNova has begun good manufacturing practice (GMP)-based master virus seed stock production of its novel intranasal SARS-CoV-2 vaccine for COVID-19.

The company is producing the seed stock using its BioComo (BC)-PIV technology and is using Millipore Sigma BioRelliance Services for manufacturing. BC-PIV is a nontransmissible viral vector co-developed by BioComo and Mie University. The BC-PIV SARS-COV-2 vaccine can be developed as an intranasal vaccine in addition to an intramuscular injection because of its high affinity to nasal and upper respiratory tract mucosa, where it is expected to induce local mucosal immunity.

The vector is derived from recombinant human parainfluenza virus type 2 (hPIV2). It is a highly efficient system that can transfer multiple foreign proteins and is designed to display not only the gene but also foreign large proteins on the surface and inside of the viral membrane. BC-PIV elicits good immunogenicity against antigen proteins without adjuvants.

Master virus seed stock is necessary to produce the BC-PIV SARS-CoV-2 vaccine. By infecting stock to the packaging cells, the BC-PIV/SARS-CoV-2 product is produced, which is recovered and purified to produce the vaccine product for clinical trials.

Sorrento to file IND for anti-SARS-CoV-2 nasal drops
Sorrento Therapeutics is filing an investigational new drug application (IND) with the U.S. Food and Drug Administration for its STI-2099 (Covi-Drops),...
AuraVax licenses intranasal vaccine platform
Vaccine biotechnology firm AuraVax Therapeutics has entered into an exclusive licensing option agreement with the University of Houston for a unique intranasal...
St. Louis school grants rights to nasal COVID-19 vaccine
Precision Virologics and Bharat Biotech obtained the rights for a new chimp-adenovirus COVID-19 vaccine from Washington University School of Medicine...
Intravacc forms public-private partnership for intranasal COVID-19 vaccine
Intravacc announced that it is partnering with Wageningen Bioveterinary Research and Utrecht University for the development of an intranasal vaccine against...

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter